Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 275 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose solution Clear all
Terminated Phase 4 Interventional Results available

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

NCT03824808
View directory record Official record
Conditions
Kidney Cancer, Prostate Cancer
Interventions
Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 20, 2026, 1:10 AM EDT
Terminated No phase listed Observational

Role of Insulin Action in Psoriasis Pathogenesis

NCT06242847
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
Interventions
Oral glucose tolerance test (OGTT), Skin punch biopsy
Diagnostic Test · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT00655850
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 20, 2026, 1:10 AM EDT
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

NCT01582061
View directory record Official record
Conditions
Cushing's Disease
Interventions
Pasireotide sub-cutaneous
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

NCT01250171
View directory record Official record
Conditions
Dry Eye
Interventions
Secukinumab 10 mg/kg, Canakinumab 10 mg/kg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 20, 2026, 1:10 AM EDT
Completed No phase listed Observational Results available

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

NCT01099397
View directory record Official record
Conditions
Prediabetic State
Interventions
Oral glucose tolerance test
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 20, 2026, 1:10 AM EDT
Withdrawn Phase 2 Interventional

NRX-1074 in Early Course Schizophrenia

NCT02603458
View directory record Official record
Conditions
Schizophrenia
Interventions
NRX-1074, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 20, 2026, 1:10 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
View directory record Official record
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Ureteral Jets on Cystoscopy

NCT02476448
View directory record Official record
Conditions
Injury of Ureter
Interventions
Normal saline, Phenazopyridine, Dextrose 10%, Sodium Fluorescein
Drug
Lead sponsor
Cecilia Calvo
Other
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 1:10 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

NCT03608033
View directory record Official record
Conditions
IgA Nephropathy
Interventions
OMS721, Vehicle (D5W or saline)
Biological · Other
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 20, 2026, 1:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sorting of Oral Sensations

NCT02390180
View directory record Official record
Conditions
Taste Qualities, Primary Tastes
Interventions
Tasting solutions
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 20, 2026, 1:10 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

NCT01538459
View directory record Official record
Conditions
Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
Interventions
Dexamethasone, Bupivacaine
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newport, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

NCT03107208
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Interventions
Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 20, 2026, 1:10 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravenous Exenatide (Byetta) During Surgery

NCT00882050
View directory record Official record
Conditions
Euglycemia, Hypoglycemia, Hyperglycemia
Interventions
Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 20, 2026, 1:10 AM EDT
Terminated Phase 4 Interventional Results available

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

NCT00896025
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

NCT00436553
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Not applicable Interventional

The Relationship Between Needle Position and Injection Pressure During Femoral Nerve Block

NCT02451813
View directory record Official record
Conditions
Orthopedic Disorders
Interventions
Apposition of needle bevel against femoral nerve
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Results available

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

NCT05953740
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-5720, Placebo to MK-5720, MK-8189, Placebo to MK-8189
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 20, 2026, 1:10 AM EDT
Withdrawn Phase 2 Interventional

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

NCT03216486
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 20, 2026, 1:10 AM EDT
Terminated Phase 2 Interventional Results available

Early Metabolic Resuscitation for Septic Shock

NCT03895853
View directory record Official record
Conditions
Multiple Organ Failure, Septic Shock, Severe Sepsis
Interventions
Best Practice, early metabolic resuscitation
Other · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

NCT05574400
View directory record Official record
Conditions
Postoperative Delirium, Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Interventions
Dextrose Water, Caffeine citrate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 1:10 AM EDT
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 20, 2026, 1:10 AM EDT